TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06305507

Intervention type: OTHER
Intervention: Focussed laser therapy
Description: Others: Spot laser therapy~Other names:~Spot laser therapy Low Level Laser Therapy (LLLT) - Local Spot~The intervention involves the precise and focused application of low-power laser on specific areas related to plantar fasciitis. The local point technique is characterized by directing the laser directly to the painful point, seeking optimal stimulation in the affected region. This approach allows for targeted delivery of treatment to the area where pain is experienced, with the goal of maximizing the effectiveness of the therapy in reducing the symptoms associated with plantar fasciitis.
Study: NCT06054984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR-T Cells Injection（GB3010 Cells Injection）
Description: The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10\^8±20%,5×10\^9±20%,5×10\^10±20%.
Study: NCT06305507

Intervention type: OTHER
Intervention: Shower laser therapy
Description: Laser Therapy Sweeping~The intervention involves constantly moving the low-power laser over the areas affected by plantar fasciitis in a sweeping pattern. The sweeping technique seeks to cover a greater extent of the painful area during each treatment session. This approach differs by providing broader stimulation across the affected area, exploring the possibility of additional benefits compared to the local spot technique.
Study: NCT04471103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Participation in a Delphi survey
Description: Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in a Delphi survey
Description: Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
Study: NCT06529562

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Surgery combined with Target-reduction intensity-modulated radiotherapy
Description: in control arm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Surgery combined with Dose-reduction intensity-modulated radiotherapy
Description: in experimental arm
Study: NCT05116982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORGONO Living Silica Acacia Gum-MMST Powder
Description: Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORGONO Living Silica Malto-OSA Powder
Description: Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
Study: NCT06071975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adezunap (AP707)
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT05814861

Intervention type: DIAGNOSTIC_TEST
Intervention: culture and PCR
Description: Stool samples will be cultured inTwo media :~A-Locke egg serum medium (LE) B- Jones' medium Then Molecular identification of Blastocystis hominis using polymerase chain reaction (PCR).

Intervention type: DIAGNOSTIC_TEST
Intervention: culture and PCR
Description: Stool samples will be cultured inTwo media :~A-Locke egg serum medium (LE) B- Jones' medium Then Molecular identification of Blastocystis hominis using polymerase chain reaction (PCR).
Study: NCT04974320

Intervention type: BIOLOGICAL
Intervention: blood biomarkers
Description: All patients were obtained blood biomarkers: troponin, ST2, copeptin

Intervention type: BIOLOGICAL
Intervention: blood biomarkers
Description: All patients were obtained blood biomarkers: troponin, ST2, copeptin

Intervention type: BIOLOGICAL
Intervention: blood biomarkers
Description: All patients were obtained blood biomarkers: troponin, ST2, copeptin

Intervention type: BIOLOGICAL
Intervention: blood biomarkers
Description: All patients were obtained blood biomarkers: troponin, ST2, copeptin
Study: NCT05992155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.
Study: NCT05336721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: 25mg/35mg/50mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000mg/m2 on Days 1-14 in a repeating 21-day cycle
Study: NCT06399471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprocessor prosthetic knee
Description: Microprocessor prosthetic knees for use in a transfemoral prosthesis
Study: NCT06284798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0650-0013 A
Description: NNC0650-0013 will be administered subcutaneously or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0650-0013 A
Description: NNC0650-0013 will be administered subcutaneously or intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration.
Study: NCT05860296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Immunotherapy
Study: NCT05702489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZX-7101A
Description: a drug to treatment influenza in Chinese adults

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: a drug to treatment influenza in Chinese adults

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: a drug to treatment influenza in Chinese adults
Study: NCT05853952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non-invasive Neuromodulation
Description: The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
Study: NCT05463887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized preventive care recommendations (decision tool)
Description: Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
Study: NCT06258785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Tizanidine 2mg will be given preoperatively prior to scheduled sacrospinous ligament suspension
Study: NCT06224153

Intervention type: OTHER
Intervention: 3-day dietary record
Description: This is the conventional ingesta assessment. It will be performed twice during the study.

Intervention type: OTHER
Intervention: Food Frequency Questionnaire (FFQ)
Description: This questionnaire is used to obtain information on the frequency of foods and drinks consumed over a period of time (1 week, 1 month...). It will be performed twice during the study.
Study: NCT04779736

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A set of implementation strategies to reduce sexual stigma
Description: The intervention will be finalized based on formative interviews and consultation with an advisory board. It is likely to include an educational mHealth component followed by an in-person workshop for skills development, then supportive coaching components (i.e., coaching calls and an optional email listserve) to encourage and respond to the implementation of recommended practices.
Study: NCT05974111

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation
Study: NCT05557292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-5552
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-5552
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-5552
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-5552
Description: Given IV
Study: NCT06431386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) Therapy
Description: Participants will receive weekly one-hour BA sessions on a day they are not receiving esketamine, delivered virtually or in person as per participant preference. The aim is for participants to learn to observe the relationship between what they did, felt, and thought and what was happening around them, and to identify conditions which maintained, increased, or weakened maladaptive behaviours. Functional behaviour analysis will be used in problem and behaviour evaluation and in planning and reviewing changes introduced by participants between sessions. Other techniques include self-observation and self-report, elaboration of activity hierarchies, behaviour programming, rehearsal and behavioural modelling, and contingency management. Between-session homework will develop relevant and rewarding routines to offer reinforcement in each participant's environment. Participants will be offered 12 BA sessions in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will receive intranasal esketamine twice weekly during the induction phase (first 4 weeks of treatment). Maintenance treatments are administered once per week or once every two weeks at the discretion of the treating physician for 8 additional weeks, totaling 12 weeks of esketamine treatment. Dosing for esketamine usually starts at 56mg on Day 1, followed by 56 or 84mg doses for subsequent treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Participants will receive intranasal esketamine twice weekly during the induction phase (first 4 weeks of treatment). Maintenance treatments are administered once per week or once every two weeks at the discretion of the treating physician for 8 additional weeks, totaling 12 weeks of esketamine treatment. Dosing for esketamine usually starts at 56mg on Day 1, followed by 56 or 84mg doses for subsequent treatments.
Study: NCT05821088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study: NCT04456517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ranolazine-matched placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ranolazine-matched placebo tablet
Study: NCT06038487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading of maxillary implant overdenture
Description: The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed loading of maxillary implant overdenture
Description: A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
Study: NCT05818943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil
Description: Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
Study: NCT06343298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MANP
Description: MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matched control
Description: This is a placebo matched vehicle - Vehicle minus the active ingredient
Study: NCT04463914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy app
Description: Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy app + EHR
Description: Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study: NCT04804007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
Study: NCT05879302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kidney Offer Shared Decision Making
Description: The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
Study: NCT06642558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)
Description: 0.25 mL per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)
Description: 0.25 mL per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)
Description: 0.25 mL per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)
Description: 0.25 mL per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)
Description: 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)
Description: 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)
Description: 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)
Description: 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline solution)
Description: 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline solution)
Description: 0.5 mL per dose
Study: NCT05116982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORGONO Living Silica Collagen Booster
Description: Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
Study: NCT05725148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART-I plus
Description: CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
Study: NCT05355363

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard Colonoscopy
Description: Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
Study: NCT05114863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A1
Description: Usual Brand (UB) filtered, non-menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: 40007388, A Non-Combusted Cigarette Variant and product use Mode A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: 40007388, A Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: 40007386, A Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A2
Description: Usual Brand (UB) filtered, menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 40007385, A Non-Combusted Cigarette Variant and product use Mode A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: 40007385, A Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: 40007387, A Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: 40007386, A Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum